> 首页 > 产品 > 一抗 > 其他 > Anti-IL-17 & TNF-alpha Reference Antibody (COVA322)

Anti-IL-17 & TNF-alpha Reference Antibody (COVA322)

Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) is 98.28%, determined by SEC-HPLC.
Cova322 bound to CTLA-8 / IL-17a protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Cova322 bound human CTLA-8 / IL-17a Protein-His, and the EC50 was 0.03639 nM.
Cova322 bound to TNFSF2 / TNFα protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Cova322 bound TNFSF2 / TNFa, and the EC50 was 0.03458 nM.
Cova322 bound to HuTNF-a-his/CHO-K(0706-32-15) cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Cova322 bound to HuTNF-a-his/CHO-K(0706-32-15) cells, and the EC50 was 99.590 nM.
The detected molecular weight of Anti-IL-17 & TNF-alpha Reference Antibody (COVA322) is 161.78 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q16552-1 & P01375
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-VHH

Additional Information
Target/Specificity	TNFSF2 / TNFa,IL-17 / IL-17A / CTLA-8
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.